Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
interferon alpha-CTP
- Development stage
- Discontinued
- Lead developer
- OPKO Health
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Administration
- Subcutaneous
01
Overview
Interferon alpha-CTP (MOD-6030) is a long-acting recombinant fusion protein developed using proprietary Carboxy Terminal Peptide (CTP) technology. Originally developed by PROLOR Biotech (later acquired by OPKO Health), the drug consists of interferon alpha-2b fused to the CTP of the beta subunit of human chorionic gonadotropin (hCG). This modification is designed to significantly extend the circulatory half-life of the interferon molecule, allowing for less frequent dosing compared to standard or pegylated interferon formulations. Like native interferon alpha, it binds to the Type I interferon receptor (IFNAR), initiating a signaling cascade that results in antiviral, antiproliferative, and immunomodulatory effects. It was primarily investigated for the treatment of chronic viral infections such as Hepatitis C and various oncology indications.
- Other names
- CTP-modified interferon alphalong-acting interferon alphainterferon alpha-2b-CTP
02
Targets
IFNAR (Immune system modulation via type I interferon receptor)
Beyond the preview
Go deeper on interferon alpha-CTP.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on interferon alpha-CTP.